Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Shivani K, Mhatre"'
Autor:
Chen Li, Ana Ferro, Shivani K. Mhatre, Danny Lu, Marcus Lawrance, Xiao Li, Shi Li, Simon Allen, Jayesh Desai, Marwan Fakih, Michael Cecchini, Katrina S. Pedersen, Tae You Kim, Irmarie Reyes-Rivera, Neil H. Segal, Christelle Lenain
Publikováno v:
Communications Medicine, Vol 2, Iss 1, Pp 1-8 (2022)
Li et al. report outcomes from the atezolizumab/isatuximab arm of the phase Ib/II MORPHEUS-CRC trial in patients with metastatic colorectal cancer. In addition, the authors leverage historical control data from the phase III IMblaze370 study to provi
Externí odkaz:
https://doaj.org/article/a2d8a6d7f97440f4b6e89b19aac1153c
Autor:
Sumanta Pal, Jun Gong, Shivani K. Mhatre, Shih-Wen Lin, Andy Surinach, Sarika Ogale, Rini Vohra, Herschel Wallen, Daniel George
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-15 (2019)
Abstract Background Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite treatment avai
Externí odkaz:
https://doaj.org/article/bd75bbb11ff940f29a493320bc5a235e
Autor:
Bruno Sangro, Robin Kate Kelley, Sairy Hernandez, Vincent E. Gaillard, Shivani K. Mhatre, Paul Dillon, Hongming Pan, Zhiqiang Meng, Yuxian Bai, Zhenggang Ren, Chia-Jui Yen, Farshid Dayyani, Andrew X. Zhu
Supplementary Figure from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68886e59f60ff6094db3f7180fdab989
https://doi.org/10.1158/1078-0432.22487250.v1
https://doi.org/10.1158/1078-0432.22487250.v1
Autor:
Bruno Sangro, Robin Kate Kelley, Sairy Hernandez, Vincent E. Gaillard, Shivani K. Mhatre, Paul Dillon, Hongming Pan, Zhiqiang Meng, Yuxian Bai, Zhenggang Ren, Chia-Jui Yen, Farshid Dayyani, Andrew X. Zhu
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a72d8b04e36f3e3aa70826863ba3454
https://doi.org/10.1158/1078-0432.22487244
https://doi.org/10.1158/1078-0432.22487244
Autor:
Bruno Sangro, Robin Kate Kelley, Sairy Hernandez, Vincent E. Gaillard, Shivani K. Mhatre, Paul Dillon, Hongming Pan, Zhiqiang Meng, Yuxian Bai, Zhenggang Ren, Chia-Jui Yen, Farshid Dayyani, Andrew X. Zhu
Purpose:Atezolizumab + bevacizumab is the new standard of care for systemic treatment-naïve, unresectable hepatocellular carcinoma (HCC). This exploratory study investigated on-treatment alpha-fetoprotein (AFP) response as a potential surrogate biom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f43ae2bc1369825266cb81b96d8b238
https://doi.org/10.1158/1078-0432.c.6532470.v1
https://doi.org/10.1158/1078-0432.c.6532470.v1
Autor:
Andrew X. Zhu, Farshid Dayyani, Chia-Jui Yen, Zhenggang Ren, Yuxian Bai, Zhiqiang Meng, Hongming Pan, Paul Dillon, Shivani K. Mhatre, Vincent E. Gaillard, Sairy Hernandez, Robin Kate Kelley, Bruno Sangro
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 16
Purpose: Atezolizumab + bevacizumab is the new standard of care for systemic treatment-naïve, unresectable hepatocellular carcinoma (HCC). This exploratory study investigated on-treatment alpha-fetoprotein (AFP) response as a potential surrogate bio
Autor:
Shivani K. Mhatre, Robson J. M. Machado, Thanh G.N. Ton, Huong Trinh, Julien Mazieres, Achim Rittmeyer, Michael T. Bretscher
BackgroundEvaluating cancer treatments in real-world data (RWD) requires informative endpoints. Due to non-standardized data collection in RWD, it is unclear if and when common oncology endpoints are approximately equivalent to their clinical trial a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5024f87683dc53391c105efe542ce14
https://doi.org/10.1101/2022.05.02.22274571
https://doi.org/10.1101/2022.05.02.22274571
Autor:
Carsten Schröder, Craig Gower-Page, Irmarie Reyes-Rivera, Arisha Patel, Richard Price, Shiraj Sen, Jessica Davies, Emily Castellanos, Jeremy Snider, Xiaobo Bai, Virginia Fisher, Shivani K. Mhatre
Publikováno v:
JCO clinical cancer informatics. 6
PURPOSE The molecular heterogeneity of metastatic colorectal cancer (mCRC) presents a therapeutic challenge, with few trials focused on patients with human epidermal growth factor receptor 2 amplification (HER2-Amp). Our limited understanding of real
Autor:
Chen Li, Ana Ferro, Shivani K. Mhatre, Danny Lu, Marcus Lawrance, Xiao Li, Shi Li, Simon Allen, Jayesh Desai, Marwan Fakih, Michael Cecchini, Katrina S. Pedersen, Tae You Kim, Irmarie Reyes-Rivera, Neil H. Segal, Christelle Lenain
Publikováno v:
Communications medicine. 2
Background Treatment for metastatic colorectal cancer patients beyond the second line remains challenging, highlighting the need for early phase trials of combination therapies for patients who had disease progression during or following two prior li
Autor:
Andy Surinach, Sumanta K. Pal, Shivani K. Mhatre, Rini Vohra, Sarika Ogale, Daniel J. George, Herschel Wallen, Shih-Wen Lin, Jun Gong
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-15 (2019)
BMC Cancer
BMC Cancer
Background Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite treatment availability,